On September 8, 2025, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) and Jiangsu Provincial Center for Disease Control and Prevention (hereinafter referred to as “Jiangsu Provincial CDC”) officially signed a strategic cooperation framework agreement in Chengdu. Centered on the core principles of “Technology-led, Collaborative Innovation, Serving People’s Livelihood”, this cooperation focuses on three core areas: vaccine R&D, disease prevention and control, and public health capacity building. It aims to promote the coordinated development of scientific research innovation, talent reserve, integration of medical treatment and prevention, and health services, focusing on advancing clinical research and evaluation of innovative vaccines, optimization of adult vaccination service systems, and upgrading of regional infectious disease prevention and control technologies, and to jointly build an integrated cooperation ecosystem of “Industry-University-Research-Application”, injecting strong impetus into the high-quality development of regional public health in Healthy Jiangsu.

At the beginning of the meeting, the relevant persons in charge of Olymvax made a special report on the progress of the tetanus medical-prevention collaborative integration construction project, introduced the current situation of tetanus prevention and treatment in Jiangsu Province in detail, and clarified the necessity of tetanus vaccination services in clinical medical institutions, laying a clear cooperation foundation for the follow-up special negotiations between the two parties.

After the report, the teams of both parties conducted in-depth special negotiations on five core topics and reached a consensus. At the end of the negotiations, representatives of Olymvax and Jiangsu Provincial CDC jointly signed the strategic cooperation framework agreement. The principals of both parties stated that this cooperation is an important practice for both parties to integrate superior resources and implement the “Healthy China 2030” strategy. In the future, relying on this agreement, both parties will deepen the collaborative innovation of “Industry-University-Research-Application”, continue to make in-depth efforts in vaccine R&D, disease prevention and control, talent training and other fields, and make greater contributions to improving the level of regional public health services in Jiangsu and safeguarding the health and well-being of the people.